Tina ★ India, 2014-05-13 18:30 (4030 d 10:08 ago) Posting: # 12938 Views: 4,819 |
|
Dear forum members, If the clinical phase of bioequivalence study is conducted before the date of expiry while the bioanalytical phase is carried for 3 months post-expiry of the product, will there be any interference with the bioanalytical values? Kind regards, Tina Edit: Subject line changed. [Helmut] |
Helmut ★★★ ![]() ![]() Vienna, Austria, 2014-05-13 18:58 (4030 d 09:40 ago) @ Tina Posting: # 12939 Views: 4,111 |
|
Hi Tina, no problem – if validation of long-term stability covers the time period from first administration to the end of analyses. Hint: The IMPs were administered within their shelf-lives. Out of curiosity: Why do you wait 3+ months to get the samples analyzed? — Dif-tor heh smusma 🖖🏼 Довге життя Україна! ![]() Helmut Schütz ![]() The quality of responses received is directly proportional to the quality of the question asked. 🚮 Science Quotes |
ElMaestro ★★★ Denmark, 2014-05-13 19:08 (4030 d 09:30 ago) @ Helmut Posting: # 12940 Views: 4,048 |
|
Hi Hötzi, ❝ Out of curiosity: Why do you wait 3+ months to get the samples analyzed? Otherwise all the waiting during validation would have been completely in vain... ![]() — Pass or fail! ElMaestro |
Tina ★ India, 2014-05-13 20:04 (4030 d 08:34 ago) @ Helmut Posting: # 12941 Views: 4,101 |
|
Thanks Helmut. Bioanalysis took a long time as sample size was 102. Additionally the CRO's HPLC machines werent available to run analysis immediately after the clinical phase. Kind regards, Tina |